Navigation Links
ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
Date:1/4/2008

DENVER, Jan. 4 /PRNewswire/ -- ARCA Discovery Inc., a privately held biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced Richard B. Brewer, President and Chief Executive Officer, will present at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8 at 2:00 PM PT.

The JPMorgan Healthcare Conference will be held January 7-10, 2008 at the Westin St. Francis in San Francisco, California.

About ARCA Discovery, Inc.

ARCA Discovery, Inc. is a privately-held biopharmaceutical company based in Denver, Colorado developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's first product is bucindolol, a next generation beta-blocker for chronic heart failure, which promises to be the first personalized, genetically-targeted cardiovascular therapy. ARCA plans to file for FDA approval of bucindolol in 2008, and to leverage its platform to develop other pharmacogenetic therapies for cardiovascular diseases. The Company recently closed a Series B round of $18 million, led by new investors Skyline Ventures and InterWest Partners. ARCA completed a $15 million Series A round in 2006 led by Atlas Venture and Boulder Ventures, which also participated in the Series B round.

About Bucindolol

ARCA has exclusive worldwide rights to bucindolol, a next generation beta-blocker for chronic heart failure. ARCA's cardiovascular platform combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development, in a unique approach that enables the efficient identification of pharmacogenetic targets. Applying this approach to bucindolol, ARCA has identified pathways affecting bucindolol response that are modulated by common genetic variations. This discovery is supported by substantial Phase 3 data, and will allow a physician to determine whether bucindolol is the right therapy for a patient with a simple genetic test. ARCA has partnered with Laboratory Corporation of America to develop the bucindolol genetic test. Prescribed by using this test, bucindolol could have significant advantages for many chronic heart failure patients. With experience in commercializing cardiovascular products, ARCA plans to market bucindolol in the U.S. through its own sales force.


'/>"/>
SOURCE ARCA Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
2. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
5. AutoGenomics Invited to Present at the JPMorgan Healthcare Conference
6. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
7. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
8. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
9. Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
10. Danaher to Present at J.P. Morgan Healthcare Conference
11. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... ... The need for blood donations in South Texas and across the nation is growing. , ... Center, blood donations are on the decline. In fact, donations across the country are at ... South Texas in the last four years alone. , There is no substitute for blood. ...
(Date:5/23/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 per share will ... of record as of the close of business on June ... of the Board of Directors and may be adjusted as ...
(Date:5/23/2016)... 23, 2016 - Leading CRO,s Use of ... - Frontage Implement a Single Platform to Manage End-to-end Operations Across ... the Bioanalytical lab Frontage Laboratories, a full-service contract research ... and China , has selected IDBS, ... addition to serving as the global electronic lab notebook (ELN), the ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
Breaking Biology Technology:
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/15/2016)... Yissum Research Development Company of the ... the Hebrew University, announced today the formation of ... various human biological indicators. Neteera Technologies has completed its ... investors. ... electromagnetic emissions from sweat ducts, enables reliable and speedy ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):